GRAIL updates cash burn guidance with $290M target as it advances Galleri FDA submission

Q3 2025 Management View CEO Robert Ragusa highlighted "Growth in Galleri volumes and revenue in the third quarter of 2025 were 39% and 29%, respectively, as uptake continues to grow." He noted that ...